EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation



Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation



Journal of Clinical Oncology 5(7): 1033-1040



From December 1982 to January 1986, 57 patients received allogeneic bone marrow transplantation as therapy for Philadelphia chromosome (Ph') positive chronic myelogenous leukemia (CML). All patients were prepared for transplantation with cyclophosphamide 60 mg/kg (day -6, -5) and fractionated total body irradiation, 165 cGy twice daily (day -4, -3, -2, -1) and received major histocompatibility (MHC) matched donor marrow (day 0). All patients received graft-v-host disease (GVHD) prophylaxis with methotrexate, prednisone, and either antithymocyte globulin (ATG) (55 patients) or OKT3 infusion (two patients). The projected survival of 29 chronic phase patients is 64% (95% confidence interval [Cl] 42% to 86%); and of 28 accelerated phase patients, 30% (95% Cl, 12% to 48%) at 30 months (P = .005). Multivariate regression analysis of pretransplant patient characteristics demonstrated that the presence of chronic phase and age less than 30 years were the only prognostic features studied that independently predicted survival. No evidence of persistent or recurrent disease has occurred in chronic phase patients; however, reappearance of the Ph' was observed in seven accelerated-phase patients, and hematologic relapse occurred in three of these seven patients. The incidence of grade II to IV acute GVHD is 63% (95% Cl, 50% to 76%) at 100 days, and that of extensive chronic GVHD is 53% (95% Cl, 33% to 74%) at 30 months. The median Karnofsky activity assessment of survivors is 100% (range, 60% to 100%), and all activity assessments less than 100% can be attributed to complications of GVHD. Bone marrow transplantation therapy for CML after preparation with cyclophosphamide and fractionated total body irradiation results in a high proportion of disease-free survival in chronic-phase patients. Survival in accelerated phase is significantly worse and is associated with relapse. GVHD has emerged as a significant cause of morbidity and mortality in this study.

(PDF emailed within 0-6 h: $19.90)

Accession: 006796662

Download citation: RISBibTeXText

PMID: 3298558

DOI: 10.1200/jco.1987.5.7.1033



Related references

Activated allogeneic cell therapy for relapsed chronic myelogenous leukemia refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. Bone Marrow Transplantation 18(6): 1153-1156, 1996

Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. Bone Marrow Transplantation 18(6): 1153-1156, 1996

Therapy options for patients in relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Annals of Hematology 73(SUPPL 2): A90, 1996

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. Journal of Clinical Oncology 11(6): 1055-1061, 1993

Comparison of the incidence of host-type hematopoiesis in patients with acute myelogenous leukemia and chronic myelogenous leukemia after sex mismatched, non-T-cell depleted, allogeneic bone marrow transplantation. Experimental Hematology (Charlottesville) 23(8): 854, 1995

Absence of influence of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood 86(10 SUPPL 1): 968A, 1995

Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet 1(8378): 665-668, 1984

Bone marrow reconstitution with normal autologous cells demonstrated by VNTR analysis after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Leukemia 11(12): 2213-2214, 1998

The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML). Leukemia & Lymphoma 11 Suppl 1: 221-226, 1993

Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. Journal of Pediatric Hematology/Oncology 24(3): 215-219, 2002

Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leukemia Research 33(9): 1291-1293, 2009

Karyotype at relapse following allogeneic bone marrow transplantation for chronic myelogenous leukemia. Cancer Genetics & Cytogenetics. 61(2): 183-192, 1992

Allogeneic, syngeneic and autologous bone marrow transplantation for chronic myelogenous leukemia. Leukemia 7(7): 1084-1086, 1993

Subdural hematoma during allogeneic bone marrow transplantation for chronic myelogenous leukemia. Acta Haematologica 88(2-3): 163-164, 1992

Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia. Blood 63(1): 219-222, 1984